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Abstract 
Diabetes has been a prevalent disease worldwide, and metformin has 
been used widely as an oral hypoglycemic agent (OHA) for type 2 
diabetes mellitus (T2DM). Its benefits include low cost, weight 
neutrality, general effect and positive efficacy for cardiovascular 
system. American Diabetes Association (ADA) has proposed diabetic 
guidelines-2020 and evaluated metformin as predominant agent. They 
include i) the preferred initial pharmacologic agent for T2DM, ii) once 
starting of metformin, it should be continued as long as tolerated 
without contraindication. Furthermore, recent studies showed safer 
effect for impaired renal function. We cannot exclude such results and 
will contribute the prevention of atherosclerotic cardiovascular disease 
(ASCVD).  
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  Diabetes has been one of the most prevalent diseases in the world (1). Adequate treatment for diabetes has 
been crucial in comprehensive manner including pharmacotherapy (2). For long years, metformin has been the 
firstly provided oral hypoglycemic agent (OHA) for type 2 diabetes mellitus (T2DM) (3). Diabetologist or 
primary care physicians have given T2DM patients metformin as a fundamental OHA. It has several 
beneficial points, such as low cost, weight neutrality and generally positive efficacy for cardiovascular system 
(3,4). 
  On the other hand, metformin has not been recommended to administer patients with chronic kidney disease 
(CKD) and/or diabetic kidney disease (DKD), because of the possible risk of lactic acidosis (5). Lots of 
diabetologists including the authors, have come to judge according to this recommendation and there was 
some tendency of withdrawal of biguanide medicine. Diabetes has been the leading cause of CKD, leading to 
DKD. Then, there have been various investigations for mutual relationships among diabetes, renal dysfunction 
and effect of metformin (3-5).  
  Several studies showed the lack of the evidence that metformin would increase lactic acidosis in patients 
with CKD (6). There are detail data concerning the value of estimated glomerular filtration rate (eGFR) 
in the following (7,8). From global outcomes for CKD, continuation of metformin is recommended for 
patients with eGFR>45mL/min/1.73m
2
 (eGFR categories G1–G3a) and patients with eGFR 30-45 
mL/min/1.73m
2 
(G3b). The discontinuation is recommended for patients with an eGFR less than 30 
mL/min/1.73m
2
 (G4– G5) (7,8). Furthermore, FDA in US has allowed metformin use for patients with eGFR 
of 45mL/min/1.73m
2
, but still restricted metformin for patients with 30 mL/min/1.73m
2
 (7). Consequently, 
metformin usage with eGFR 30-45 mL/min/1.73m
2
 has been controversial (7,8).  
  As to a recent report, no difference was observed regarding to lactic acidosis events among metformin and 
other OHAs (6). A few papers showed the beneficial effects of long-term use of metformin, with controversial 
results (9-11). Consequently, there are some trials associated with the hypothesis that metformin use for CKD 
would be beneficial in the light of incidence of lactic acidosis, mortality and prevalence of end-stage renal 
disease (ESRD).  
  From several reports mentioned above until 2019, perspectives for metformin have been developed with 
evidences. In 2020, ADA proposed the official comment in the standard of medical care in diabetes (12). 
Among them, comprehensive approaches are observed from various points of view. ADA proposes patient-
centered collaborative care and recommends diabetes care by a multidisciplinary team with subspecialty 
physicians, primary care physicians, nurse practitioners, and other hygiene professionals (12). The goal of 
diabetic therapy would be to optimize Quality of Life (QOL) and to delay diabetic complications. 
Furthermore, therapeutic plan needs to include patient-based values and preferences (12). The principle of 
diabetic treatment has three factors, which are nutrition, exercise and references. 
  Regarding pharmacologic approaches, the preferred initial pharmacologic agent for long period is metformin 
(level A) (13). ADA guideline shows that once starting of metformin, it should be continued as long as it can 
be tolerated without contraindication. If needed, other agents and insulin would be added to fundamental 
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prescription of metformin (level A). In some patients, early combination treatment can be considered at the 
initiation of OHA (level A).  
  Among these, patient-centered care has to be applied to decided which pharmacologic agents to be chosen 
(13). They include various factors, such as cost, influence on weight, risk for adverse effects, hypoglycemia 
risk and cardiovascular comorbidities (13,14). In particular, important perspectives are possible development 
of atherosclerotic cardiovascular disease (ASCVD) and indicators of high ASCVD risk, CKD, and heart 
failure (HF) (15).  
  As first line diabetic agent consists, metformin has been safe, effective and inexpensive agent, and may 
reduce cardiovascular events and mortality. It can be useful for immediate release form for once or twice 
administration daily. When compared with sulfonylurea agents, it has beneficial efficacy on weight, HbA1c 
and cardiovascular outcomes (16). Except metformin, there has been little systematic result for other OHAs 
available for initial treatment of T2DM.  
  As to the reverse effects of metformin, gastrointestinal tract symptoms such as abdominal discomfort, 
diarrhea and bloating have been observed. Metformin in the blood is cleared through renal filtration, and 
elevated circulating levels may cause lactic acidosis. It has been known before, but this situation has been 
found to be rather rare (17). Consequently, metformin is now evaluated to be safe even in patients with lower 




  There was a recent randomized trial with confirmation of previous data that metformin may cause vitamin 
B12 deficiency with exacerbation of neuropathy (17). This result was consistent with a report from diabetes 
prevention program outcomes study (DPPOS), which recommends examination of vitamin B12 concentration 
(17,18).  
  Since T2DM is usually progressive, monotherapy of metformin can be possible for a few years. After that, 
combination treatment would be necessary in order to add stepwise medications. This approach is recently 
revealed to be superior to sequential addition of other medications for primary and secondary development 
(19). Based on a comparative meta-analysis report, additional therapy to initial metformin administration 
shows reduction of HbA1c about 0.7-1.0% (20). When HbA1c target will not be achieved for 3 months, 
metformin plus other agent can be started with any of following six options. They are dipeptidyl peptidase‐4 
(DPP‐4) inhibitors, sodium-glucose cotransporter-2 (SGLT2) Inhibitors, sulfonylurea, thiazolidinedione, 
glucagon-like peptide-1 receptor agonists (GLP-1 Ras) and basal insulin (13).  
  Among these six options, GLP-1 Ras have been highly evaluated for the efficacy for T2DM. When T2DM 
patient needs greater blood glucose lowering, GLP-1Ras are recommended for preference to insulin if it is 
possible (level B). (13). Furthermore, recent reports can support clinical efficacy of GLP-1 Ras. Most GLP-1 
Ras are injectable, but a new oral formulation of semaglutide is available at present (21). In contrast, some 
reports investigating the efficacy between GLP-1 RAs and insulin have showed similar results (22,23).  
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  From economic diabetic treatment point of view, cost for diabetes has been increased for two decades (24). 
Medication cost may become major stress for diabetic patients influencing adherence with regular medication 
(25). Then, metformin has been very economic for long years with benefit for patients. From this point, 
metformin is a useful OHA. 
  In summary, metformin has been one of the most useful OHA for long. Recent investigation showed the 
beneficial and safe effect for patients with impaired renal function. This will be expected to become a 
reference for diabetic practice and research.  
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